Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 4, pp. 387-405
Open Access | Times Cited: 303

Showing 26-50 of 303 citing articles:

Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors
Alberto Pïcca, Giulia Berzero, Kévin Bihan, et al.
Neurology Neuroimmunology & Neuroinflammation (2021) Vol. 8, Iss. 3
Open Access | Times Cited: 46
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Olivier Michielin, Aly‐Khan A. Lalani, Caroline Robert, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 1, pp. e003024-e003024
Open Access | Times Cited: 35
Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy
Melissa G. Lechner, Mandy I. Cheng, Anushi Y. Patel, et al.
The Journal of Immunology (2022) Vol. 209, Iss. 4, pp. 696-709
Open Access | Times Cited: 29
Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers—Emerging Strategies for Clinical Management
Carla Ferrándiz‐Pulido, Ulrike Leiter, Catherine Α. Harwood, et al.
Transplantation (2023) Vol. 107, Iss. 7, pp. 1452-1462
Closed Access | Times Cited: 18
Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events
Avinash Rao Ullur, Gabrielle Côté, Karyne Pelletier, et al.
Clinical Kidney Journal (2023) Vol. 16, Iss. 6, pp. 939-951
Open Access | Times Cited: 18
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Emanuel Raschi, Simone Rossi, Andrea De Giglio, et al.
Drug Safety (2023) Vol. 46, Iss. 9, pp. 819-833
Open Access | Times Cited: 18
The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function
Karen Tsai, Huiyan Ma, Tom Z. Liang, et al.
Thyroid (2024) Vol. 34, Iss. 2, pp. 158-166
Closed Access | Times Cited: 7
Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records
Virginia H. Sun, Julius C. Heemelaar, Ibrahim Hadžić, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 7
Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies
Seok Jin Kim, Sang Eun Yoon, Won Seog Kim
Annals of Laboratory Medicine (2024) Vol. 44, Iss. 3, pp. 210-221
Open Access | Times Cited: 6
Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable
Sikander Ailawadhi, Leyla Shune, Sandy W. Wong, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 5, pp. e217-e225
Open Access | Times Cited: 6
Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis
Panpan Luo, Yuge Guo, Yang He, et al.
Investigational New Drugs (2024) Vol. 42, Iss. 4, pp. 369-375
Closed Access | Times Cited: 6
Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors and CAR-T Cell Therapy: A Comprehensive Imaging-Based Review
Chiara Pozzessere, Bianca Mazini, Patrick Omoumi, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2585-2585
Open Access | Times Cited: 6
Peripheral nervous system immune-related adverse events due to checkpoint inhibition
M.J. O’Hare, Amanda C. Guidon
Nature Reviews Neurology (2024) Vol. 20, Iss. 9, pp. 509-525
Closed Access | Times Cited: 6
Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
Qi Li, Mengran Cao, Guosheng Yuan, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 27
Focusing on colorectal cancer in young adults (Review)
Virginia Constantinou, Constantina Constantinou
Molecular and Clinical Oncology (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 14
Cancer immunotherapy focusing on the role of interleukins: A comprehensive and updated study
Mahmoud Samadi, Amin Kamrani, Hadi Nasiri, et al.
Pathology - Research and Practice (2023) Vol. 249, pp. 154732-154732
Closed Access | Times Cited: 13
Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology
Vincenzo Quagliariello, Margherita Passariello, Isabella Bisceglia, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 5
Impact of diagnostic investigations in the management of CAR T-cell-associated neurotoxicity
Matteo Mauget, Sophie Lemercier, Quentin Quelven, et al.
Blood Advances (2024) Vol. 8, Iss. 10, pp. 2491-2498
Open Access | Times Cited: 5
Safety and clinical efficacy of neoadjuvant chemoradiation therapy with immunotherapy for organ preservation in ultra-low rectal cancer: preliminary results of the CHOICE-I trial: a prospective cohort study
Leqi Zhou, Guanyu Yu, Yuxin Shen, et al.
International Journal of Surgery (2025) Vol. 111, Iss. 3, pp. 2487-2494
Open Access
The impact of obesity and its related underlying diseases on cytokine release syndrome and the efficacy of CAR-T therapy in treating B-cell malignancies
Mengyi Du, Rosanna Tryphene Massounga Mayombo, Jiachen Liu, et al.
Research Square (Research Square) (2025)
Closed Access
Managing adverse effects of novel immunotherapies in pancreatic and colon cancers
Zohaib Ahmed, Zahoor Ahmad, Sarfraz Ahmad
Elsevier eBooks (2025), pp. 341-361
Closed Access
Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
Ting Yan, Minghui Long, Chaoyi Liu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease
Allison Yan, Lauren M. Madigan, Abraham M. Korman, et al.
American Journal of Clinical Dermatology (2025)
Open Access
Endocrinological toxicities related to immunotherapy combinations for advanced renal cell carcinoma: practical expert-based management recommendations
Carla Colombo, Simone De Leo, Ilaria Campisi, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104627-104627
Closed Access
Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia
Qianyi Zhou, Yuxin An, Xiaomei Zhang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access

Scroll to top